TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals Limited announced the successful passing of all resolutions during its 2025 Annual General Meeting. Key resolutions included the adoption of the remuneration report, re-election of a director, approval of convertible notes issuance, and renewal of takeover provisions. These decisions are expected to strengthen the company’s governance and financial strategies, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for treating various medical conditions. The company is known for its innovative approaches and market focus on providing solutions for unmet medical needs.
Average Trading Volume: 1,134,797
Technical Sentiment Signal: Sell
Current Market Cap: A$150M
Learn more about PAR stock on TipRanks’ Stock Analysis page.